A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2

被引:154
作者
Suarez, S. Cebe
Pieren, M.
Cariolato, L.
Arn, S.
Hoffmann, U.
Bogucki, A.
Manlius, C.
Wood, J.
Ballmer-Hofer, K. [1 ]
机构
[1] Paul Scherrer Inst, Lab Biomol Res, CH-5232 Villigen, Switzerland
[2] Friedrich Miescher Inst, CH-4058 Basel, Switzerland
[3] Novartis Pharma Ltd, CH-4057 Basel, Switzerland
关键词
VEGF; splicing; heparin; neuropilin; tyrosine kinase; angiogenesis; signal transduction; MAP kinase;
D O I
10.1007/s00018-006-6254-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The development of functional blood and lymphatic vessels requires spatio-temporal coordination of the production and release of growth factors such as vascular endothelial growth factors (VEGFs). VEGF family proteins are produced in multiple isoforms with distinct biological properties and bind to three types of VEGF receptors. A VEGF-A splice variant, VEGF-A(165)b, has recently been isolated from kidney epithelial cells. This variant is identical to VEGF-A(165) except for the last six amino acids encoded by an alternative exon. VEGF-A(165)b and VEGF-A(165) bind VEGF receptors 1 and 2 with similar affinity. VEGF-A(165)b elicits drastically reduced activity in angiogenesis assays and even counteracts signaling by VEGF-A(165). VEGF-A(165)b weakly binds to heparan sulfate and does not interact with neuropilin-1, a coreceptor for VEGF receptor 2. To determine the molecular basis for altered signaling by VEGF-A(165)b we measured VEGF receptor 2 and ERK kinase activity in endothelial cells in culture. VEGF-A(165) induced strong and sustained activation of VEGF receptor 2 and ERK-1 and -2, while activation by VEGF-A(165)b was only weak and transient. Taken together these data show that VEGF-A(165)b has attenuated signaling potential through VEGF receptor 2 defining this new member of the VEGF family as a partial receptor agonist.
引用
收藏
页码:2067 / 2077
页数:11
相关论文
共 66 条
[1]   INCREASED VASCULAR ENDOTHELIAL GROWTH-FACTOR LEVELS IN THE VITREOUS OF EYES WITH PROLIFERATIVE DIABETIC-RETINOPATHY [J].
ADAMIS, AP ;
MILLER, JW ;
BERNAL, MT ;
DAMICO, DJ ;
FOLKMAN, J ;
YEO, TK ;
YEO, KT .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1994, 118 (04) :445-450
[2]   Molecular mechanisms of lymphangiogenesis in health and disease [J].
Alitalo, K ;
Carmeliet, P .
CANCER CELL, 2002, 1 (03) :219-227
[3]  
Bates DO, 2002, CANCER RES, V62, P4123
[4]   Vascular endothelial growth factor and the nervous system [J].
Brockington, A ;
Lewis, C ;
Wharton, S ;
Shaw, PJ .
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2004, 30 (05) :427-446
[5]   Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives [J].
Caldwelll, RB ;
Bartoli, M ;
Behzadian, MA ;
El-Remessy, AEB ;
Al-Shabrawey, M ;
Platt, DH ;
Caldwell, RW .
DIABETES-METABOLISM RESEARCH AND REVIEWS, 2003, 19 (06) :442-455
[6]   Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188 [J].
Carmeliet, P ;
Ng, YS ;
Nuyens, D ;
Theilmeier, G ;
Brusselmans, K ;
Cornelissen, I ;
Ehler, E ;
Kakkar, VV ;
Stalmans, I ;
Mattot, V ;
Perriard, JC ;
Dewerchin, M ;
Flameng, W ;
Nagy, A ;
Lupu, F ;
Moons, L ;
Collen, D ;
D'Amore, PA ;
Shima, DT .
NATURE MEDICINE, 1999, 5 (05) :495-502
[7]   Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele [J].
Carmeliet, P ;
Ferreira, V ;
Breier, G ;
Pollefeyt, S ;
Kieckens, L ;
Gertsenstein, M ;
Fahrig, M ;
Vandenhoeck, A ;
Harpal, K ;
Eberhardt, C ;
Declercq, C ;
Pawling, J ;
Moons, L ;
Collen, D ;
Risau, W ;
Nagy, A .
NATURE, 1996, 380 (6573) :435-439
[8]   Vascular endothelial growth factor enhances atherosclerotic plaque progression [J].
Celletti, FL ;
Waugh, JM ;
Amabile, PG ;
Brendolan, A ;
Hilfiker, PR ;
Dake, MD .
NATURE MEDICINE, 2001, 7 (04) :425-429
[9]   STRUCTURAL REQUIREMENTS FOR DIMERIZATION, GLYCOSYLATION, SECRETION, AND BIOLOGICAL FUNCTION OF VPF/VEGF [J].
CLAFFEY, KP ;
SENGER, DR ;
SPIEGELMAN, BM .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 1995, 1246 (01) :1-9
[10]   VEGF(121), A VASCULAR ENDOTHELIAL GROWTH-FACTOR (VEGF) ISOFORM LACKING HEPARIN-BINDING ABILITY, REQUIRES CELL-SURFACE HEPARAN SULFATES FOR EFFICIENT BINDING TO THE VEGF RECEPTORS OF HUMAN-MELANOMA CELLS [J].
COHEN, T ;
GITAYGOREN, H ;
SHARON, R ;
SHIBUYA, M ;
HALABAN, R ;
LEVI, BZ ;
NEUFELD, G .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (19) :11322-11326